Ipamorelin + CJC-1295

Overview

Ipamorelin and CJC-1295 are two distinct growth-hormone-releasing peptides that are frequently prescribed together in compounded "GH secretagogue" protocols. They're paired because they act on two different receptors with complementary pharmacology, not because they're the same drug. Ipamorelin is a pentapeptide that mimics ghrelin, binding the growth hormone secretagogue receptor (GHS-R1a) to stimulate pituitary GH release. It was specifically designed to be more receptor-selective than older GHRPs like GHRP-6, producing GH release with less cortisol, prolactin, and appetite stimulation at typical research doses.⁸

CJC-1295 is a modified analog of growth-hormone-releasing hormone, GRF(1-29). The version most often compounded includes a Drug Affinity Complex (DAC) — a chemical linker that binds circulating albumin and extends the peptide's half-life from minutes (like native GHRH or sermorelin) to nearly a week.¹ A non-DAC version, sometimes called "Mod GRF 1-29," behaves much more like standard GHRH, with a roughly 30-minute half-life.

Also known as: Ipamorelin (Aib-His-D-2-Nal-D-Phe-Lys-NH2); CJC-1295 (modified GRF 1-29, with or without DAC). Neither compound has ever held FDA approval or a commercial trade name — both exist only as compounded or research-chemical products. Combining a GHRH analog with a ghrelin-mimetic GHRP is a recognized pharmacologic strategy in endocrine physiology, since the two act through independent signaling pathways to produce a larger GH pulse than either alone.⁶ But — and this is the central honesty point of this page — direct combination trials of ipamorelin plus CJC-1295 in humans are essentially absent from the peer-reviewed literature. The practice of co-administering them is extrapolated from separate single-agent data, not from a dedicated trial of the pair.

How it works

Ipamorelin binds the ghrelin receptor (GHS-R1a), a Gq/G11-coupled receptor found on pituitary somatotrophs and hypothalamic neurons. Activation triggers phospholipase C, IP3 signaling, and intracellular calcium release, which stimulates GH secretion. Its main pharmacologic selling point — less cortisol, aldosterone, and prolactin stimulation than first-generation GHRPs — rests mainly on preclinical pharmacology and small early-phase studies rather than large modern human trials.⁸

CJC-1295 binds the GHRH receptor, a Gs-coupled receptor, activating the same adenylate cyclase/cAMP/PKA cascade as native GHRH and sermorelin. The DAC modification's covalent albumin-binding is the key innovation: it shields the peptide from renal clearance and DPP-IV enzymatic degradation, converting what would otherwise be a sub-15-minute half-life into one lasting nearly a week.

The foundational human pharmacokinetic study for CJC-1295 with DAC found a plasma half-life of 5.8 to 8.1 days across two randomized, double-blind, placebo-controlled ascending-dose studies in healthy adults. A single subcutaneous dose produced dose-dependent GH increases of 2- to 10-fold sustained for six or more days, and IGF-1 increases of 1.5- to 3-fold lasting 9–11 days; with repeated dosing, IGF-1 stayed elevated for up to 28 days.¹ Ipamorelin, by contrast, has a short plasma half-life of roughly two hours, which is why compounded protocols typically pair a long-acting CJC-1295 injection (nightly or 1–2x weekly for the DAC version) with more frequent — often daily — ipamorelin dosing. Both peptides are administered subcutaneously.

What the research shows

Animal / preclinical evidence

The rationale for combining a GHRH analog with a GHRP comes from classic endocrine physiology work — studies by researchers including Bowers and Veldhuis in the 1980s and 1990s — establishing that pairing these two receptor classes produces synergistic (greater than additive) GH release compared to either alone.⁶ This is a generalization from other GHRH/GHRP pairings studied at the time, not preclinical or clinical proof specific to ipamorelin and CJC-1295 together.

Human evidence

CJC-1295's key human data come from Teichman et al. (2006): two randomized, double-blind, placebo-controlled ascending-dose studies (28 and 49 days) in healthy adults aged 21–61, which established the multi-day half-life and sustained GH/IGF-1 elevation described above, with no serious adverse events reported.¹ Ipamorelin's human data come from smaller, older Phase 1/2 pharmacology studies sponsored by Novo Nordisk (its original developer) in healthy volunteers and limited patient populations. These studies suggested a favorable selectivity profile versus older GHRPs, but were small — typically dozens of subjects — and the program was discontinued before Phase 3 trials or FDA approval.⁸

There is no published randomized controlled trial evaluating ipamorelin plus CJC-1295 together for any indication — muscle building, fat loss, sleep, or longevity. All dosing conventions seen in compounding and clinical practice literature are derived from separate single-agent pharmacokinetics and general synergy theory, not from a trial of the pair itself. Neither peptide has been studied in a modern randomized trial for the indications for which the combination is most heavily marketed today. No long-term (multi-year) safety data exist for either compound alone or in combination; the longest controlled human CJC-1295 data run to about 49 days.

Typical use and dosing

Published dosing below reflects research and clinical-practice literature — it is educational context, not a prescribing recommendation. An Aurafil physician determines actual dosing individually based on labs, goals, and medical history.

None of these dosing patterns come from a validated trial of the combination. They reflect clinical and compounding-pharmacy convention, built on separate single-agent pharmacokinetic data.

Safety, side effects, and who should avoid it

Common side effects reported with both agents include injection-site reactions (redness, swelling, itching), flushing, headache, and mild dizziness. Ipamorelin is reported to cause less prolactin, cortisol, and appetite stimulation than older GHRPs such as GHRP-6 — a frequently cited selling point, though it rests on limited comparative data rather than large trials.⁸

Case reports and pharmacovigilance discussions have raised concerns about immunogenicity — antibody formation against the DAC-albumin conjugate — though this hasn't been robustly quantified in large trials. Class-wide theoretical risks tied to GH-axis stimulation include insulin resistance or impaired glucose tolerance, fluid retention, carpal-tunnel-type symptoms, joint aches, and a theoretical concern about stimulating occult malignancy given IGF-1's growth-promoting effects — none of which have combination-specific outcome data. In clinical practice, IGF-1 and fasting glucose or HbA1c are commonly monitored, following general GH-axis therapy convention, though this is a practice pattern rather than a trial-validated protocol.

Regulatory status

Neither ipamorelin nor CJC-1295 is FDA-approved for any indication. Both were placed in FDA 503A Category 2 — bulk substances presenting potential significant safety risks, disqualified from compounding — in the FDA's September 29, 2023 interim policy update.² In September 2024, the original nominators of ipamorelin acetate and CJC-1295 (with and without DAC) withdrew their nominations, which removed the formal Category 2 listing.⁴ Withdrawal is not the same as approval: as of mid-2026, these substances aren't on any FDA 503A category list at all, leaving their compounding legality dependent on ordinary Section 503A eligibility criteria rather than an affirmative clearance.⁵

Neither peptide is currently under active review in the FDA's July 2026 Pharmacy Compounding Advisory Committee agenda, which covered BPC-157, TB-500, KPV, MOTS-c, DSIP, Semax, and Epitalon — meaning their regulatory path forward is presently less defined than for those actively-reviewed peptides.

Both CJC-1295 and ipamorelin fall under the WADA 2026 Prohibited List (Section S2.2.4, covering GHRH analogs and growth hormone secretagogues), prohibited at all times, in and out of competition.⁷ No specialty medical society — including the group behind the AACE/ACE 2019 Clinical Practice Guideline for Growth Hormone Deficiency in Adults — has issued a position statement endorsing ipamorelin, CJC-1295, or their combination for anti-aging, muscle-building, or athletic use; that guideline explicitly discusses "unapproved uses of GH" without endorsing GH secretagogues for these purposes.⁶

Frequently asked questions